Article
Oncology
Lisi M. Dredze, Michael Friger, Samuel Ariad, Michael Koretz, Bertha Delgado, Ruthy Shaco-Levy, Margarita Tokar, Michael Bayme, Ravit Agassi, Maia Rosenthal, Victor Dyomin, Olga Belochitski, Shai Libson, Tamar Mizrahi, David B. Geffen
Summary: This study analyzed the outcomes of neoadjuvant chemotherapy for breast cancer using doxorubicin-cyclophosphamide followed by weekly paclitaxel. The results showed that this treatment can be safely administered in real-world settings and has a high rate of complete pathological response.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Dario Trapani
Summary: The Oncology Grand Rounds series aims to provide clinical context for original reports published in the Journal. It includes case presentations, discussions on diagnostic and management challenges, reviews of relevant literature, and summaries of suggested management approaches. The series helps readers understand how to apply key study results to their own clinical practice.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Julia Foldi, Andrea Silber, Emily Reisenbichler, Kamaljeet Singh, Neal Fischbach, Justin Persico, Kerin Adelson, Anamika Katoch, Nina Horowitz, Donald Lannin, Anees Chagpar, Tristen Park, Michal Marczyk, Courtney Frederick, Trisha Burrello, Eiman Ibrahim, Tao Qing, Yalai Bai, Kim Blenman, David L. Rimm, Lajos Pusztai
Summary: The Phase I/II trial aimed to evaluate the safety and efficacy of durvalumab in combination with other therapies for triple-negative breast cancer. The study found that the combination treatment resulted in a 44% pathologic complete response rate, with some patients experiencing grade 3/4 adverse events. Results suggest potential benefits of the combination therapy, particularly in patients with high stromal tumor-infiltrating lymphocytes.
Article
Oncology
Lynn Symonds, Isaac Jenkins, Hannah M. Linden, Brenda Kurland, Julie R. Gralow, Vijayakrishna V. K. Gadi, Georgiana K. Ellis, Qian Wu, Eve Rodler, Pavani Chalasani, Xiaoyu Chai, Jinny Riedel, Scca Network Investigators, Alison Stopeck, Ursa Brown-Glaberman, Jennifer M. Specht
Summary: Neoadjuvant sunitinib combined with paclitaxel, doxorubicin, and cyclophosphamide chemotherapy regimen can improve the pathologic complete response rate in patients with locally advanced and inflammatory breast cancer. ER-positive patients have a higher response rate, indicating promising incremental benefit.
CLINICAL BREAST CANCER
(2022)
Article
Oncology
Manabu Futamura, Kazuhiro Ishihara, Yasuko Nagao, Atsuko Ogiso, Yoshimi Niwa, Takumi Nakada, Yoshihiro Kawaguchi, Ai Ikawa, Iwao Kumazawa, Ryutaro Mori, Mai Kitazawa, Yoshiki Hosono, Masashi Kuno, Mana Kawajiri, Akira Nakakami, Makoto Takeuchi, Akemi Morikawa, Yoshihisa Tokumaru, Yasuo Katagiri, Yoshimasa Asano, Yoshinori Mushika, Toshio Shimokawa, Nobuhisa Matsuhasih
Summary: In this study, nab-PTX plus trastuzumab and pertuzumab showed a high pCR rate in HER2-positive breast cancer, especially in the HER2 subtype. Although there were some adverse events, they were generally acceptable, indicating that this regimen is safe and effective as neoadjuvant chemotherapy for HER2-positive breast cancer.
Article
Oncology
Xian Wu, Chaoran Ye, Xingmeng Wang, Ruyu Cai, Junzhe Yang, Xiafei Yu, Yi Zhou, Li Shen, Yanhui Zhu, Xiaoan Liu
Summary: This study retrospectively analyzed the efficacy and toxicity of epirubicin plus cyclophosphamide followed by docetaxel (EC-D) and epirubicin plus cyclophosphamide followed by paclitaxel (EC-P) as neoadjuvant chemotherapy regimens. The results showed that the rate of pathological complete response (pCR) was higher in EC-P compared to EC-D. Patients with ER (-), PR (-), Her-2 (+), and high Ki-67 index were more likely to achieve pCR with EC-P.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Oncology
Haiyan Zhang, Zhiping Fan, Fen Huang, Lijie Han, Yajing Xu, Na Xu, Lan Deng, Shunqing Wang, Dongjun Lin, Xiaodan Luo, Qing Zhang, Xiaodan Liu, Xudong Li, Xinquan Liang, Shuangfeng Xie, Hong Qu, Sijian Yu, Hongsheng Zhou, Pengcheng Shi, Li Xuan, Ren Lin, Hui Liu, Hua Jin, Jing Sun, Qifa Liu
Summary: A randomized phase III trial in China compared busulfan plus cyclophosphamide (BuCy) regimen with total body irradiation plus cyclophosphamide (TBI-Cy) regimen as conditioning for allo-HSCT in adult standard-risk B-cell-ALL patients. The study found that BuCy regimen had noninferior efficacy and safety compared to TBI-Cy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Andreas Hagen Rossevold, Nikolai Kragoe Andresen, Christina Annette Bjerre, Bjornar Gilje, Erik Hugger Jakobsen, Sunil Xavier Raj, Ragnhild Sorum Falk, Hege Giercksky Russnes, Thea Jahr, Randi Ruud Mathiesen, Jon Lomo, Oystein Garred, Sudhir Kumar Chauhan, Ragnhild Reehorst Lereim, Claire Dunn, Bjorn Naume, Jon Amund Kyte
Summary: This study evaluated the efficacy and safety of adding atezolizumab to immune-stimulating chemotherapy in patients with metastatic triple-negative breast cancer. The results showed that the combination treatment improved progression-free survival but also increased the occurrence of adverse events.
Article
Mathematical & Computational Biology
Weibao Hu, Mengli Song, Linfeng Li
Summary: ACT chemotherapy regimen in breast cancer patients may increase the risk of cardiotoxic events.
COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE
(2022)
Article
Oncology
Tomofumi Naruse, Souichi Yanamoto, Mitsunobu Otsuru, Nobuhiro Yamakawa, Tadaaki Kirita, Yukari Shintani, Tatsushi Matsumura, Masaya Okura, Masashi Sasaki, Yoshihide Ota, Shin-ichi Yamada, Hiroshi Kurita, Masahiro Umeda
Summary: The study suggests that the weekly cetuximab plus paclitaxel regimen may be a treatment option for patients with recurrent or metastatic oral squamous cell carcinoma that is refractory to platinum-based chemotherapy or progressive disease after chemotherapy. Adverse events were tolerable and manageable, with overall efficacy being relatively promising.
ANTICANCER RESEARCH
(2021)
Article
Oncology
O. Gluz, S. Kuemmel, U. Nitz, M. Braun, K. Luedtke-Heckenkamp, R. von Schumann, M. Darsow, H. Forstbauer, J. Potenberg, C. Uleer, E. M. Grischke, B. Aktas, C. Schumacher, C. zu Eulenburg, R. Kates, K. Jozwiak, M. Graeser, R. Wuerstlein, R. Baehner, M. Christgen, H. H. Kreipe, N. Harbeck
Summary: In high-risk HR+/HER2- early breast cancer, nanoparticle albumin-bound (nab)-paclitaxel showed promising efficacy versus solvent-based (sb)-paclitaxel in neoadjuvant trials. However, optimal patient and therapy selection remains a topic of ongoing research.
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
Yin Liu, Lei Fan, Zhong-Hua Wang, Zhi-Ming Shao
Summary: This study evaluated the efficacy and safety of nab-paclitaxel followed by dose-dense epirubicin/cyclophosphamide as neoadjuvant therapy in patients with triple-negative breast cancer, showing promising anti-tumor activity and acceptable tolerability.
Article
Oncology
Hironaga Satake, Hiroki Hashida, Hiroaki Tanioka, Yasuhiro Miyake, Shinichi Yoshioka, Takanori Watanabe, Masato Matsuura, Takahisa Kyogoku, Michio Inukai, Takeshi Kotake, Yoshihiro Okita, Toshihiko Matsumoto, Hisateru Yasui, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
Summary: The three-month adjuvant CAPOX treatment is well-tolerated and may be a promising strategy for post-curative resection of CLM, showing potential effectiveness and tolerability for patients.
Article
Multidisciplinary Sciences
Makoto Nakamura, Yusuke Meguri, Shuntaro Ikegawa, Takumi Kondo, Yuichi Sumii, Takuya Fukumi, Miki Iwamoto, Yasuhisa Sando, Hiroyuki Sugiura, Noboru Asada, Daisuke Ennishi, Shuta Tomida, Emi Fukuda-Kawaguchi, Yasuyuki Ishii, Yoshinobu Maeda, Ken-ichi Matsuoka
Summary: Alpha-galactosylceramide (alpha-GC) administration after reduced-dose posttransplantation cyclophosphamide (PTCy) efficiently restores GVHD-preventing activity and maintains the GVL effect, providing important insights for optimizing transplantation strategies.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Claudia Marchetti, Riccardo Tudisco, Vanda Salutari, Antonella Pietragalla, Giovanni Scambia, Anna Fagotti
Summary: This study aims to evaluate whether the combination of olaparib with standard chemotherapy in the neoadjuvant setting can improve tumor response, with the hypothesis that adding a poly adenosine diphosphate-ribose polymerase inhibitor will achieve a higher response rate in BRCA mutated patients. The trial will enroll 35 eligible patients with III-IV stage ovarian, peritoneal, or fallopian tube cancer for evaluation.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2021)